Skip to main content
Premium Trial:

Request an Annual Quote

Greg Lucier, Bill Castell, Joe Hogan, Thomas McLain, Agilent, Expression Analysis, ExonHit



Former Abbott Laboratories vice president of sales and marketing for Abbott Spine, Todd Fanning, has been hired as president of privately held BioMedical Enterprises, a bone-fixation and musculoskeletal-research company.

Genentech has appointed three new vice presidents: David Broad will become vice president and general manager of the company's Oceanside product operations; John Pinion will be vice president of external quality; and Michael Varney has been appointed vice president of small molecule drug discovery.

Broad will be responsible for the facilities and engineering, information technology, manufacturing, and manufacturing technology departments at the Oceanside facility, the company said. He will report to Patrick Yang, senior vice president of product operations. His appointment is tied to Genentech's acquisition of the Oceanside facility from Biogen, which Broad has served as vice president and general manager of its West Coast manufacturing operations since October 2000. Prior to that position, Broad was vice president of development and manufacturing at Cell Genesys. He holds a BS and a PhD in microbiology from the University of London.

John Pinion, the incoming vice president of external quality, will report to Robert Garnick, the company's senior vice president of regulatory, quality and compliance. He currently serves as vice president of quality, renal, cellular therapies at Baxter Japan. Pinion was previously vice president of quality, global systems and North American operations at Baxter BioScience, and he has also served as director of quality in medical device manufacturing at Imagyn Medical. Pinion holds a BS mechanical engineering from West Virginia University.

Michael Varney, Genentech's incoming vice president of small molecule drug discovery, will report to Marc Tessier-Lavigne, the senior vice president of research drug discovery. He currently serves as vice president of drug discovery at Pfizer Global Research and Development. He served in several roles at Agouron Pharmaceuticals until the company's acquisition by Pfizer, culminating with a position as vice president and head of research. He holds a BS in chemistry from the University of California, Los Angeles, and a PhD in organic synthesis from the California Institute of Technology.

Peter Leddy will join Invitrogen as senior vice president of human resources effective July 5. He most recently served as vice president of human resources for the Americas operations of Dell. Leddy will oversee Invitrogen's global HR strategy and report directly to CEO Greg Lucier

General Electric said that Bill Castell, CEO of GE Healthcare, will retire next year. He will be replaced by Joe Hogan upon his retirement. The appointment was included in an announcement about the realigning of GE's businesses.

Thomas McLain has been appointed to the board of directors of the Biotechnology Industry Organization effective June 21, 2005. McLain is one of 11 new board members, who will each serve two-year terms.

McLain is currently the chairman, CEO and president of Nabi Pharmaceuticals. Prior to joining Nabi Pharmaceuticals in 1998, McLain was employed by Bausch & Lomb.

New Releases

Agilent Technologies last week released its Zebrafish Oligo Microarray and Mouse Development Oligo Microarray 44K.

The Zebrafish array contains 21,495 probes that represent genes from public databases like RefSeq and Unigene, Agilent said, as well as QC probes for monitoring experimental variations.

Agilent's Mouse Development Oligo Microarray 44K contains 44,041 probes representing mouse genes and transcripts from the National Institute of Aging Mouse Gene Index. The company recommends the tool for the study of stem cells and developmental biology.

Expression Analysis last week introduced its Globin Reduction Service, an enhancement of the company's RNA isolation services, that reduces interference in globin mRNAs to increase the sensitivity of detection of microarray transcripts in blood, the company said. The service can be performed on whole blood from PreAnalytiX PAXgene Blood RNA Tubes or Applied Biosystems Tempus Blood RNA Tubes, according to the microarray genetics testing and analysis organization.

ExonHit Therapeutics last week made available its Cytokine SpliceArrays through the company's SpliceArray Service business unit. The company released splice variant arrays for an apoptosis gene family last month, and has also made arrays for nuclear/co-regulators, GPCR, and ion channel families available since the service launched last February.

ExonHit said that the newest array, which is printed by Agilent Technologies, can be used for research into immunity, inflammation, and hematopoiesis. Arrays for other gene families will be made available in coming months, the company said.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.